Top-News

Intensity Therapeutics Aktie News

Aktie
WKN:  A3C9BX ISIN:  US45828J1034 US-Symbol:  INTS Branche:  Biotechnologie Land:  USA
0,5063 $
+0,0533 $
+11,77%
0,43482 € 05.12.25
Depot/Watchlist
Marktkapitalisierung *
17,76 Mio. €
Streubesitz
83,75%
KGV
-1,59
Index-Zuordnung
-

Intensity Therapeutics News

13.05.25 - PR Newswire
Intensity Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Intensity Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update PR Newswire
06.05.25 - PR Newswire
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Receive European Medicines Agency Authorization to Initiate Phase 2 INVINCIBLE-4 (SAKK/66/22) Study for INT230-6 in the Treatment of Presurgical Triple-Negative Breast Cancer in France
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Receive European Medicines Agency Authorization to Initiate Phase 2 INVINCIBLE-4 ...
25.04.25 - PR Newswire
Intensity Therapeutics, Inc. Announces $2.35 Million Public Offering
Intensity Therapeutics, Inc. Announces $2.35 Million Public Offering PR Newswire
13.03.25 - PR Newswire
Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update
Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update PR Newswire
28.01.25 - PR Newswire
Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") Following Periodic Review
Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") Following Periodic ...
10.01.25 - PR Newswire
Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6
Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6 PR Newswire
12.12.24 - PR Newswire
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial, INVINCIBLE-4 (SAKK
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, ...

Newssuche

Videos

newspaper
05.12.25 +1,73%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »